The FDA again rejected an application for the expanded use of the anticoagulant rivaroxaban to treat patients with acute coronary syndrome. The drug has been cleared for six other indications.
Published in Brief:
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||